OMCL or HIMS: Which Is the Better Value Stock Right Now?
Hims' obesity drug business may get boost as employers drop coverage
Hims & Hers Health, Inc. (HIMS) Sees a More Significant Dip Than Broader Market: Some Facts to Know
A Look at Hims & Hers Health Inc (HIMS) After 5.4% Decline -- GF Value $38.53 vs Price $33.54
Hims & Hers Health, Inc. (HIMS) Is a Trending Stock: Facts to Know Before Betting on It
Hims & Hers Stock Jumps After Barclays Raises Price Target
Living Longer Is Big Business. These Stocks Will Benefit.
Hims & Hers: The Bull Case Remains Strong
Hims & Hers Health, Inc. (HIMS) Ascends While Market Falls: Some Facts to Note
Hims & Hers Enters A New Phase
Hims & Hers Health Stock Slides Friday: What's Going On?
The GLP-1 stock nobody is pricing in isn't a drugmaker
Why Hims & Hers Health, Inc. (HIMS) Dipped More Than Broader Market Today
OMCL vs. HIMS: Which Stock Is the Better Value Option?
Hims & Hers Health (HIMS) Up 15.8% Since Last Earnings Report: Can It Continue?
Is It Too Late to Buy Hims & Hers Health Inc (HIMS) After 3.7% Rally? GF Value Says Undervalued
Investors Heavily Search Hims & Hers Health, Inc. (HIMS): Here is What You Need to Know
Great News: Wall Street Is Turning Bullish on This Troubled Telehealth Stock
Skip the Oura Ring IPO. Buy These 10 Stocks Instead.
Hims & Hers Names Dr. Anant Vinjamoori as Chief Medical Officer of Hims
Hims & Hers Names Dr. Anant Vinjamoori as Chief Medical Officer of Hims
Hims & Hers Expands With Eucalyptus Acquisition
Hims & Hers Completes Acquisition of Eucalyptus, Advancing its Position as the World's Largest Consumer Health Platform
Hims & Hers Completes Acquisition of Eucalyptus, Advancing Position as the World's Largest Consumer Health Platform
Hims & Hers Completes Acquisition of Eucalyptus, Expanding Access to Comprehensive, Clinically-Backed Weight Management Care in Germany
Hims & Hers Completes Acquisition of Eucalyptus, Parent Company of Juniper, Officially Entering Japanese Market
Hims & Hers Completes Acquisition of Eucalyptus, Accelerating Its Push to Transform Healthcare for Canadians
Hims & Hers Completes Acquisition of Eucalyptus, Advancing its Position as the World's Largest Consumer Health Platform
Is Hims & Hers Stock an Undervalued Stock to Buy?
Hims & Hers Expands Integrated Health Access via Platform Expansion
Hims & Hers Expands Benefits for Active Subscribers With Eight New Health and Wellness Partners
Hims & Hers Expands Benefits for Active Subscribers With Eight New Health and Wellness Partners
Hims & Hers Eyes Global Growth: Will $1.15B Eucalyptus Deal Fuel Its Recovery or Dilute Shareholders?
Hims & Hers Stock Spikes -- Insider Sends Strong Signal With $1 Million Buy
Hims & Hers Gains 5% on Insider Buying
HIMS vs. TEM: Which AI Healthcare Stock Offers Better Upside Now?
Hims & Hers Shares Rally On Million-Dollar Insider Purchase
Hims & Hers faces steep climb to hit 2026 guidance as Wegovy churn risk looms, says BofA
Hims & Hers faces steep climb to hit 2026 guidance as Wegovy churn risk looms, says BofA
Here is What to Know Beyond Why Hims & Hers Health, Inc. (HIMS) is a Trending Stock
Hims & Hers Deepens Personalized Care Through Platform Expansion
Hims offers Apotex's generic semaglutide in Canada after Novo patent expiry
Hims & Hers Expands GLP-1 Offering in Canada with Generic Semaglutide
Hims & Hers Brings First-Time Access to Generic Semaglutide to Canada
Hims & Hers: Wegovy Deal Fuels Growth
Hims & Hers Massive Stock Drop Explained
Hims & Hers Prices Upsized $350 Million Convertible Notes Offering
Hims & Hers Stock Stabilizes After Upsized $350 Million Convertible Note Offering
Hims & Hers Health, Inc. Prices Upsized $350 Million Convertible Senior Notes Offering to Support International Expansion and Accelerate AI-Driven Platform Investment
Hims & Hers Falls on Planned $300 Million Convertible Debt Offering